This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Horizon Pharma (HZNP) Tops Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Pharma (HZNP) delivered earnings and revenue surprises of 30.00% and 3.39%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Is A Disappointment in Store for Tilray (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on pipeline progress and updates when Tilray (TLRY) reports third-quarter results.
Endo (ENDP) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Investors are expected to focus on the Xiaflex performance and pipeline updates when Endo (ENDP) reports third-quarter results.
Horizon Pharma (HZNP) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Horizon Pharma (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Pharma (HZNP) Down 1.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Horizon Pharma Completes Enrollment in Eye Disease Study
by Zacks Equity Research
Horizon Pharma (HZNP) completes early enrollment for the confirmatory phase III study of teprotumumab, which is being evaluated for the treatment of thyroid eye disease.
Horizon Pharma (HZNP) Boasts Robust Pipeline Amid Competition
by Zacks Equity Research
Horizon Pharma (HZNP) remains focused on advancing its pipeline candidates and is also making efforts to expand the label of its already approved drugs.
Horizon Pharma (HZNP) Q2 Earnings & Sales Beat, Shares Rise
by Zacks Equity Research
Horizon Pharma (HZNP) beat earnings and sales estimates in the second quarter of 2018.
Horizon Pharma (HZNP) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Horizon Pharma (HZNP) delivered earnings and revenue surprises of 65.52% and 8.92%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in Store for Horizon Pharma (HZNP) in Q2 Earnings?
by Zacks Equity Research
During the second-quarter earnings call, Horizon Pharma (HZNP) will focus on the performance of business units along with that of Actimmune and Krystexxa and update on teprotumumab's development.
Is a Beat in Store for BioDelivery (BDSI) in Q2 Earnings?
by Zacks Equity Research
Investor focus will be on the performance of BioDelivery Sciences' (BDSI) two marketed drugs, Belbuca (chronic pain) and Bunavail (opioid-dependence).
Is a Beat in the Cards for Nektar (NKTR) in Q2 Earnings?
by Zacks Equity Research
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
What Lies in Store for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology is expected to drive milestone and royalty payments in second-quarter 2018.
What's in the Cards for Arena (ARNA) This Earnings Season?
by Zacks Equity Research
With no marketed product, investors will likely focus on Arena's (ARNA) efforts to develop its pipeline on second-quarter earnings call.
What's in Store for ImmunoGen (IMGN) This Earnings Season?
by Zacks Equity Research
ImmunoGen's (IMGN) considerable progress with lead pipeline candidate, mirvetuximab soravtansine, is expected to drive investor interest in the second-quarter earnings call.
Is a Beat in Store for Vertex (VRTX) This Earnings Season?
by Zacks Equity Research
Vertex Pharma (VRTX) is expected to beat estimates when it reports second-quarter earnings on Jul 25.
Is a Beat in Store for Bristol-Myers (BMY) in Q2 Earnings?
by Zacks Equity Research
Bristol-Myers (BMY) is scheduled to report second-quarter earnings on Jul 26.
HZNP vs. LGND: Which Stock Is the Better Value Option?
by Zacks Equity Research
HZNP vs. LGND: Which Stock Is the Better Value Option?
Why Is Horizon Pharma (HZNP) Up 18.3% Since Its Last Earnings Report?
by Zacks Equity Research
Horizon Pharma (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Kitov (KTOV) Gets Approval from FDA for Consensi, Shares Up
by Zacks Equity Research
Kitov Pharma (KTOV) gained as the FDA approved Consensi (amlodipine and celecoxib) oral tablets for the treatment of osteoarthritis pain and hypertension.
Horizon Pharma (HZNP) Q1 Earnings & Sales Miss, Shares Fall
by Zacks Equity Research
Horizon Pharma (HZNP) misses earnings and sales estimates in Q1. However, the orphan unit and the rheumatology business continue to grow.
Horizon Pharma (HZNP) Q1 Loss Wider, Revenues Miss
by Indrajit Bandyopadhyay
Horizon Pharma (HZNP) missed earnings and sales estimates in the first quarter.
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.
Zacks.com highlights: Western Digital, Daqo New Energy, Horizon Pharma Public and American Axle & Manufacturing Holdings
by Zacks Equity Research
Zacks.com highlights: Western Digital, Daqo New Energy, Horizon Pharma Public and American Axle & Manufacturing Holdings
4 Low P/CF Stocks Ready to Add Value to Your Investment
by Zacks Equity Research
One of the important factors that make P/CF a highly dependable metric is that operating cash flow adds back non-cash